This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
CASSS Associate Directors
Share |

Our Leadership

Board of Directors

Associate Directors

Distinguished Fellows

Staff

 

 

 

 

Digital Strategy Report

 

    

Associate Directors (ADs) are “statutory members” of CASSS.  Membership in this committee is open to all who have participated as a volunteer on any of the CASSS meeting committees and who actively parcticipate in AD activities. In most professional societies you pay dues to join the organization.  In this way, CASSS is unique.  Our “dues” are participation instead of a monetary payment.  CASSS' ADs are a select group of members, made up of those who care enough about the organization to not just send in an annual check but actually contribute their time and expertise.  This is what gives us our strength. The ADs are also the members of CASSS charged with electing the Board and advising them on issues of importance to the membership-at-large.

Siddharth Advant, Celgene Corporation, United States

Wasfi Al-Azzam, GlaxoSmithKline, United States

Kris Antonsen, BioMarin Pharmaceutical Inc., United States

Thomas Arroll, Seattle Genetics, Inc., United States

Yves Aubin, Health Canada, Canada

Sandra Auguste-Bower, H. Lundbeck A/S, Denmark

Evangelos Bakopanos, Health Canada, Canada

Jared Bee, MacroGenics, Inc., United States

Edna Betgovargez, SCIEX, United States

Markus Bluemel, Novartis Pharma AG, Switzerland

Timothy Blanc, Eli Lilly and Company, United States

Michael Boyne, COUR Pharmaceuticals Development Company, Inc., United States

Michael Brenowitz, Albert Einstein College of Medicine, United States

Greg Cantin, Five Prime Therapeutics Inc, United States

Holly Cargill, Pfizer, Inc., United States

David Carr, Bioanalytical Technologies, United States

James Carroll, Pfizer, Inc., United States

Jennifer Chadwick, BioAnalytix, Inc., United States

Andrew Chang, Novo Nordisk Inc., United States

Michael Chang, Bluebird Bio, Inc., United States

Emmanuelle Charton, EDQM, Council of Europe, France

Guodong Chen, Bristol-Myers Squibb Company, United States

Barry Cherney, Amgen Inc., United States

Judy Chou, Bayer, United States

Natalie Ciaccio, BioMarin Pharmaceutical Inc., United States

David Cirelli, Pfizer, Inc., United States

Steven Cohen, SAC Analytical Consultants, United States

Mary Cromwell, Genentech, a Member of the Roche Group, United States

Robert Cunico, Pacific Biolabs, United States

Xiao-Ping Dai, WuXi Advanced Therapies, United States

Eef Dirksen, Synthon Biopharmaceuticals B.V., Netherlands

Bharat Dixit, Finch Therapeutics Group, United States

John Dobbins, Eli Lilly and Company, United States

Vladislav Dolnik, Alcor BioSeparations LLC, United States

Narasaiah Dontha, Celgene Corporation, United States

Roman Drews, Daiichi Sankyo, Inc., United States

Anders Dybdal Nielsen, Novo Nordisk A/S, Denmark

Julia Edwards, Allergan, United States

William Egan, GlaxoSmithKline Vaccines, United States

Christof Finkler, F. Hoffmann - La Roche Ltd., Switzerland

Frantisek Foret, Institute of Analytical Chemistry ASCR, v.v.i., Czech Republic

Kathleen Francissen, Genentech, a Member of the Roche Group, United States

Michelle Frazier, Coherus Biosciences, United States

John Frenz, NA, United States

Marta Germano, Janssen Vaccines and Prevention, Netherlands

Joseph Glajch, JLG AP Consulting LLC, United States

Ralf Gleixner, Ares Trading SA, An affiliate of Merck Serono, Switzerland

Andras Guttman, SCIEX, United States

Fadi Hakki, Viela Bio, United States

Jason Hampson, Amgen Inc., United States

Mei Han, Amgen Inc., United States

Stephen Hartman, AbbVie Inc., United States

Julie Heflin, Abbvie Inc., United States

John Hennessey, NovaDigm Therapeutics, Inc., United States

John Hobbs, Beckman Coulter, Inc., United States

Damian Houde, Codiak Biosciences, United States

Ping Hu, Janssen R&D, LLC, United States

Chi-Ting Huang, Surface Oncology, United States

Brendan Hughes, Bristol-Myers Squibb Company, United States

Ronald Imhoff, Janssen Vaccines and Prevention, Netherlands

Xu-Rong Jiang, AstraZeneca BioVentures, United States

Guifeng Jiang, Boehringer Ingelheim Pharmaceuticals, Inc., United States

Carmilia Jimenez Ramirez, Ajinomoto Bio-Pharma Services, United States

Peter Johnson, RETIRED, United States

Franka Kalman, HES-SO Valais, Switzerland

Vinaya Kapoor, Tricida, United States

Jon Kauffman, Eurofins Advantar, United States

Sarah Kennett, Genentech, a Member of the Roche Group, United States

Maura Kibbey, USP, United States

Steffen Kiessig, F. Hoffmann - La Roche Ltd., Switzerland

John Kim, Teva Pharmaceuticals, United States

Kevin King, Pfizer, Inc., United States

Alistair Kippen, IPSEN Biopharm Ltd., United Kingdom

Yasuhiro Kishioka, Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Junichi Koga, Daiichi Sankyo Co., Ltd., Japan

Carol Krantz, Seattle Genetics, Inc., United States

Robert Kuhn, Amgen Inc., United States

Joseph Kutza, MedImmune, A member of the AstraZeneca Group, United States

Nathan Lacher, Pfizer, Inc., United States

Ineui Lee, Kobe University, Graduate School of Science and Technology Innovation, Japan

Kathy Lee, Eli Lilly and Company, United States

David Lee, Bluebird Bio, Inc., United States

Patricia Lewis, Alipine Immune Sciences, United States

Vivian Lindo, MedImmune Limited, United Kingdom

Aston Liu, GlaxoSmithKline, United States

Anthony Lubiniecki, University of Maryland, Baltimore County, United States

Anders Lund, Synlogic, United States

Jiann-Kae Luo, Regeneron Pharmaceuticals, Inc., United States

Michelle Lytle, Eli Lilly and Company, United States

Yelena Lyubarskaya, Sanofi, United States

Mirek Macka, University of Tasmania,

Helena Madden, Biogen, United States

Khalid Mahmood, Eli Lilly and Company, United States

John Marino, National Institute of Standards and Technology (NIST), United States

Ingrid Markovic, Genentech, a Member of the Roche Group, United States

Philip Marriott, Monash University, Australia

William Matousek, Regeneron Pharmaceuticals, Inc., United States

Noriyuki Matsumoto, Japan Pharmaceutical Manufacturers Association (JPMA), Japan

Robert Mattaliano, Genzyme, a Sanofi Company, United States

Rob McCombie, Sangamo Therapeutics, Inc., United States

Bruce Meiklejohn, Meiklejohn Consulting, United States

David Michels, Genentech, a Member of the Roche Group, United States

Kenneth Miller, AstraZeneca, United States

Thomas Millward, Novartis Pharma AG, Switzerland

Anthony Mire-Sluis, AstraZeneca, United States

Edwin Moore, University of Illinois, United States

Jamie Moore, Genentech, a Member of the Roche Group, United States

Genesio Murano, BioScope Associates, United States

Linda Narhi, Amgen Inc., United States

Wassim Nashabeh, F. Hoffmann - La Roche Ltd., United States

Jens Bjorn Nielsen, Novo Nordisk A/S, Denmark

Shawn Novick, Seattle Genetics, Inc., United States

Brian Nunnally, Seqirus, a CSL Company, United States

Fionnuala O'Driscoll, Eli Lilly Kinsale Limited, Ireland

Julia O'Neill, Tunnell Consulting, Inc., United States

Bhavin Parekh, Eli Lilly and Company, United States

SungAe Park, Samsung Bioepis Co., Ltd., Korea, South

Jun Park, ViroMed Co., Ltd, Korea, South

David Passmore, RubrYc Therapeutics, Inc., United States

Stefanie Pluschkell, Pfizer, Inc., United States

Christopher Pohl, Thermo Fisher Scientific, United States

Francis Poulin, Sanofi, United States

Lesley Redfern, AbbVie Inc., United States

Gang Ren, Lawrence Berkeley National Laboratory, United States

Daisy Richardson, Merck & Co., Inc., United States

Anthony Ridgway, BGTD, Health Canada, Canada

Noel Rieder, Amgen Inc., United States

Nadine Ritter, Global Biotech Experts, LLC, United States

Sushmita Roy, BioMarin Pharmaceutical Inc., United States

Margaret Ruesch, Pfizer, Inc., United States

Reb Russell, Jazz Pharmaceuticals, United States

Richard Rustandi, Merck & Co., Inc., United States

Catharina Sanger -van de Griend, Kantisto BV, Netherlands

Michael Sadick, Catalent Pharma Solutions, United States

Oscar Salas-Solano, Seattle Genetics, Inc., United States

Mark Schenerman, CMC Biotech-MAS Consulting, United States

John Schiel, NIST, United States

Martin Schiestl, Sandoz GmbH, Austria

Timothy Schofield, GlaxoSmithKline, United States

Thomas Schreitmueller, F. Hoffmann - La Roche Ltd., Switzerland

Sally Seaver, Seaver Associates LLC, United States

Joanne Severs, Bayer Pharma AG, United States

Karin Sewerin, BioPharmaLinx AB, Sweden

Zahra Shahrokh, ZDev Consulting and STC Biologics, United States

Joseph Siemiatkoski, J Siemiatkoski Consulting, United States

Satish Singh, Lonza AG, United States

Robert Sitrin, PATH, United States

Lance Smallshaw, UCB Biopharma sprl., Belgium

Zoran Sosic, Biogen, United States

Kannan Srinivasan, Thermo Fisher Scientific, United States

Arne Staby, Novo Nordisk A/S, Denmark

Jeff Staecker, BioPhia Consulting, Inc., United States

Robert Stevenson, American Laboratory/Labcompare, United States

Annie Sturgess, Bristol-Myers Squibb Company, United States

Shelley Suggett, Halozyme Therapeutics, United States

Frantisek Svec, Lawrence Berkeley National Laboratory, United States

Patrick Swann, Amgen Inc., United States

Jonathan Sweedler, University of Illinois at Urbana-Champaign, United States

Garry Takle, Merck & Co., Inc., United States

Harold Taylor, Merz Pharma GmbH & Co KGaA, Germany

Max Tejada, MedImmune, A member of the AstraZeneca Group, United States

Hansjoerg Toll, Novartis, Austria

Kazuhisa Uchida, Kobe University, Japan

Paul Varley, MedImmune Limited, United Kingdom

Kimberly Vazquez, Immunomedics, Inc., United States

Hermann Wätzig, University of Braunschweig, Germany

Michael Washabaugh, Adello Biologics, LLC, United States

Ziping Wei, BridgeBio LLC, United States

Andrew Weiskopf, Biogen, United States

William Weiss, Eli Lilly and Company, United States

Jolanda Westerlaken, UCB Pharma SA, Canada

Lance Wong, Strand Bio, United States

Jason Wood, Bruker Corporation, United States

Philip Wyatt, Wyatt Technology Corporation, United States

Yuan Xu, Merck Research Laboratories, United States

Toyohiko Yamamoto, Asahi Kasei Pharma Corporation, Japan

Min Young, Ultragenyx Pharmaceutical Inc., United States

Christopher Yu, Genentech, a Member of the Roche Group, United States

Heidi Zhang, Juno Therapeutics, A Celgene Company, United States

Eike Zimmermann, Boehringer Ingelheim Pharmaceuticals, Inc., United States

 

 

    

 

more Calendar

1/28/2019 » 1/31/2019
CMC Strategy Forum and WCBP 2019

1/29/2019 » 1/31/2019
WCBP 2019 Live Stream

3/12/2019 » 3/13/2019
CMC Strategy Forum Latin America 2019

Featured Members
William Weiss, Eli Lilly and CompanyFind out more about Will in this month's Member Spotlight!

Membership Software Powered by YourMembership  ::  Legal